Related references
Note: Only part of the references are listed.Sodium-glucose cotransporter 2 (SGLT-2) inhibitors and microvascular outcomes in patients with type 2 diabetes: systematic review and meta-analysis
E. G. Dorsey-Trevino et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2020)
Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes
Ghadeer K. Dawwas et al.
DIABETES OBESITY & METABOLISM (2019)
Sodium-glucose co-transporter-2 inhibitor use and risk of lower-extremity amputation: Evolving questions, evolving answers
Jeff Y. Yang et al.
DIABETES OBESITY & METABOLISM (2019)
Lower limb events in individuals with type 2 diabetes: evidence for an increased risk associated with diuretic use
Louis Potier et al.
DIABETOLOGIA (2019)
Canagliflozin should be prescribed with caution to individuals with type 2 diabetes and high risk of amputation
Matilde Monteiro-Soares et al.
DIABETOLOGIA (2019)
Resurgence of Diabetes-Related Nontraumatic Lower-Extremity Amputation in the Young and Middle-Aged Adult US Population
Linda S. Geiss et al.
DIABETES CARE (2019)
Risks of diabetic foot syndrome and amputation associated with sodium glucose co-transporter 2 inhibitors: A Meta-analysis of Randomized Controlled Trials
D. Li et al.
DIABETES & METABOLISM (2018)
Limb- and Person-Level Risk Factors for Lower-Limb Amputation in the Prospective Seattle Diabetic Foot Study
Edward J. Boyko et al.
DIABETES CARE (2018)
Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D)
Patrick B. Ryan et al.
DIABETES OBESITY & METABOLISM (2018)
Risk of amputations associated with SGLT2 inhibitors compared to DPP-4 inhibitors: A propensity-matched cohort study
Sruthi Adimadhyam et al.
DIABETES OBESITY & METABOLISM (2018)
Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World)
Jacob A. Udell et al.
CIRCULATION (2018)
Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes
Hsien-Yen Chang et al.
JAMA INTERNAL MEDICINE (2018)
Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study
Peter Ueda et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: A retrospective cohort study
Zhong Yuan et al.
DIABETES OBESITY & METABOLISM (2018)
Risk of lower limb amputation in a national prevalent cohort of patients with diabetes
Jason K. Gurney et al.
DIABETOLOGIA (2018)
Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials
Serge Jabbour et al.
DIABETES OBESITY & METABOLISM (2018)
Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias?
Samy Suissa
DIABETES CARE (2018)
Long-term efficacy and safety of sodium-glucose cotransporter-2 inhibitors as add-on to metformin treatment in the management of type 2 diabetes mellitus A meta-analysis
Jian Li et al.
MEDICINE (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
SGTL2 inhibitors and amputations in the US FDA Adverse Event Reporting System
Gian Paolo Fadini et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Diabetic foot ulcer carries high amputation and mortality rates, particularly in the presence of advanced age, peripheral artery disease and anemia
Rafael Henrique Rodrigues Costa et al.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS (2017)
Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials
Sven Kohler et al.
ADVANCES IN THERAPY (2017)
Lower-limb amputation following foot ulcers in patients with diabetes: classification systems, external validation and comparative analysis
Matilde Monteiro-Soares et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2015)
Data Resource Profile: Clinical Practice Research Datalink (CPRD)
Emily Herrett et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2015)
Epidemiology of Type 2 Diabetic Foot Problems and Predictive Factors for Amputation in China
Yufeng Jiang et al.
INTERNATIONAL JOURNAL OF LOWER EXTREMITY WOUNDS (2015)
Comparative Efficacy and Safety of Antidiabetic Drug Regimens Added to Metformin Monotherapy in Patients with Type 2 Diabetes: A Network Meta-Analysis
Elizabeth S. Mearns et al.
PLOS ONE (2015)
Changes in Diabetes-Related Complications in the United States, 1990-2010
Edward W. Gregg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
SGLT inhibitors in management of diabetes
Abd A. Tahrani et al.
LANCET DIABETES & ENDOCRINOLOGY (2013)
Variation in the recorded incidence of amputation of the lower limb in England
N. Holman et al.
DIABETOLOGIA (2012)
Share Paper
